These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 36700997)

  • 1. The effect of tetrahydrocannabinol:cannabidiol oromucosal spray on cognition: a systematic review.
    Motaghi E; Ghasemi-Pirbaluti M; Rashidi M; Alasvand M; Di Ciano P; Bozorgi H
    Eur J Clin Pharmacol; 2023 Mar; 79(3):371-381. PubMed ID: 36700997
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The influence of THC:CBD oromucosal spray on driving ability in patients with multiple sclerosis-related spasticity.
    Celius EG; Vila C
    Brain Behav; 2018 May; 8(5):e00962. PubMed ID: 29761015
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of tetrahydrocannabinol:cannabidiol oromucosal spray on activities of daily living in multiple sclerosis patients with resistant spasticity: a retrospective, observational study.
    Mallada Frechín J
    Neurodegener Dis Manag; 2018 Jun; 8(3):151-159. PubMed ID: 29851356
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Can oral fluid cannabinoid testing monitor medication compliance and/or cannabis smoking during oral THC and oromucosal Sativex administration?
    Lee D; Karschner EL; Milman G; Barnes AJ; Goodwin RS; Huestis MA
    Drug Alcohol Depend; 2013 Jun; 130(1-3):68-76. PubMed ID: 23146820
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tetrahydrocannabinol:Cannabidiol Oromucosal Spray for Multiple Sclerosis-Related Resistant Spasticity in Daily Practice.
    Vermersch P; Trojano M
    Eur Neurol; 2016; 76(5-6):216-226. PubMed ID: 27732980
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma cannabinoid pharmacokinetics following controlled oral delta9-tetrahydrocannabinol and oromucosal cannabis extract administration.
    Karschner EL; Darwin WD; Goodwin RS; Wright S; Huestis MA
    Clin Chem; 2011 Jan; 57(1):66-75. PubMed ID: 21078841
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tetrahydrocannabinol and cannabidiol oromucosal spray in resistant multiple sclerosis spasticity: consistency of response across subgroups from the SAVANT randomized clinical trial.
    Meuth SG; Henze T; Essner U; Trompke C; Vila Silván C
    Int J Neurosci; 2020 Dec; 130(12):1199-1205. PubMed ID: 32065006
    [No Abstract]   [Full Text] [Related]  

  • 8. Sativex
    Markovà J; Essner U; Akmaz B; Marinelli M; Trompke C; Lentschat A; Vila C
    Int J Neurosci; 2019 Feb; 129(2):119-128. PubMed ID: 29792372
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Delta-9-tetrahydrocannabinol/cannabidiol (Sativex®): a review of its use in patients with moderate to severe spasticity due to multiple sclerosis.
    Syed YY; McKeage K; Scott LJ
    Drugs; 2014 Apr; 74(5):563-78. PubMed ID: 24671907
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Newest evidence for tetrahydrocannabinol:cannabidiol oromucosal spray from postapproval pragmatic studies.
    Patti F
    Neurodegener Dis Manag; 2019 Apr; 9(2s):3-7. PubMed ID: 30657027
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A double-blind, randomized, placebo-controlled, parallel-group study of THC/CBD oromucosal spray in combination with the existing treatment regimen, in the relief of central neuropathic pain in patients with multiple sclerosis.
    Langford RM; Mares J; Novotna A; Vachova M; Novakova I; Notcutt W; Ratcliffe S
    J Neurol; 2013 Apr; 260(4):984-97. PubMed ID: 23180178
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Newest evidence for tetrahydrocannabinol:cannabidiol oromucosal spray from randomized clinical trials.
    Marková J
    Neurodegener Dis Manag; 2019 Apr; 9(2s):9-13. PubMed ID: 30657024
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cannabidiol (CBD) content in vaporized cannabis does not prevent tetrahydrocannabinol (THC)-induced impairment of driving and cognition.
    Arkell TR; Lintzeris N; Kevin RC; Ramaekers JG; Vandrey R; Irwin C; Haber PS; McGregor IS
    Psychopharmacology (Berl); 2019 Sep; 236(9):2713-2724. PubMed ID: 31044290
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of Previous Failed Antispasticity Therapy on the Efficacy and Tolerability of THC:CBD Oromucosal Spray for Multiple Sclerosis Spasticity.
    Haupts M; Vila C; Jonas A; Witte K; Álvarez-Ossorio L
    Eur Neurol; 2016; 75(5-6):236-43. PubMed ID: 27160412
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An open-label extension study to investigate the long-term safety and tolerability of THC/CBD oromucosal spray and oromucosal THC spray in patients with terminal cancer-related pain refractory to strong opioid analgesics.
    Johnson JR; Lossignol D; Burnell-Nugent M; Fallon MT
    J Pain Symptom Manage; 2013 Aug; 46(2):207-18. PubMed ID: 23141881
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tetrahydrocannabinol/Cannabidiol Oromucosal Spray in Patients With Multiple Sclerosis: A Pilot Study on the Plasma Concentration-Effect Relationship.
    Contin M; Mancinelli L; Perrone A; Sabattini L; Mohamed S; Scandellari C; Foschi M; Vacchiano V; Lugaresi A; Riva R
    Clin Neuropharmacol; 2018; 41(5):171-176. PubMed ID: 30024443
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Critical Review of the Role of the Cannabinoid Compounds Δ
    Jones É; Vlachou S
    Molecules; 2020 Oct; 25(21):. PubMed ID: 33113776
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Palatability and oral cavity tolerability of THC:CBD oromucosal spray and possible improvement measures in multiple sclerosis patients with resistant spasticity: a pilot study.
    Lus G; Cantello R; Danni MC; Rini A; Sarchielli P; Tassinari T; Signoriello E
    Neurodegener Dis Manag; 2018 Apr; 8(2):105-113. PubMed ID: 29683408
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase I study to assess the single and multiple dose pharmacokinetics of THC/CBD oromucosal spray.
    Stott CG; White L; Wright S; Wilbraham D; Guy GW
    Eur J Clin Pharmacol; 2013 May; 69(5):1135-47. PubMed ID: 23179176
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The detection of THC, CBD and CBN in the oral fluid of Sativex® patients using two on-site screening tests and LC-MS/MS.
    Molnar A; Fu S; Lewis J; Allsop DJ; Copeland J
    Forensic Sci Int; 2014 May; 238():113-9. PubMed ID: 24699310
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.